Skip to content

aTyr Pharma ATYR EPS (Diluted)

EPS (Diluted) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.31+9.2%
Merck & Co. logo
Merck & Co.MRK
-$1.72-186%
United Therapeutics logo
United TherapeuticsUTHR
$5.82-12.2%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
-$0.29+6.5%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
-$0.34+19.0%
Vor Biopharma logo
Vor BiopharmaVOR
-$5.11+1.9%

Other financials

Income statement

See full
Revenue-
Operating income-$11.4M+27.5%
Net income-$10.8M+27.5%

Balance sheet

See full
Cash & equivalents$10.0M-3.4%
Total debt$12.3M-9.2%
Total equity$57.9M-22.8%
Total assets$79.7M-18.1%

Cash flow

See full
Operating cash flow-$12.5M+18.8%
CapEx$138.0K
Free cash flow-$12.7M+17.9%

Valuation

See full
Market cap$54.88M-88.2%
Enterprise value$57.17M
P/S288.8×

Profitability

See full
Operating margin-40,856.3%+28,833pp
Net margin-39,009.5%+29,653pp
FCF margin-32,664.7%+4,018pp

Returns & leverage

See full
Return on equity-105.3%+50.6pp
Debt / equity0.2×0.0×
Current ratio5.8×-2.0×

Where this comes from

Reported directly by aTyr Pharma in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: aTyr Pharma’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about aTyr Pharma's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is aTyr Pharma's EPS (diluted)?
aTyr Pharma (ATYR) reported EPS (diluted) of -$0.11 in Q1 2026.
How has aTyr Pharma's EPS (diluted) changed year-over-year?
aTyr Pharma's EPS (diluted) increased by 35.3% year-over-year, from -$0.17 to -$0.11.
What is the long-term trend for aTyr Pharma's EPS (diluted)?
Over 4 years (2021 to 2025), aTyr Pharma's EPS (diluted) has grown at a -18.4% compound annual growth rate (CAGR), from -$1.78 to -$0.79.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.